Chemomab Therapeutics Ltd. (CMMB) Company Overview

What does Chemomab Therapeutics do?

Chemomab Therapeutics Ltd. is an Israeli, Nasdaq-listed clinical-stage biotechnology company centered on nebokitug, formerly CM-101, a humanized monoclonal antibody that neutralizes CCL24. Chemomab argues that CCL24 sustains inflammation and fibrosis, so blocking it may interrupt both processes. Its investor overview describes a focus on immune-fibrotic diseases with high unmet need.

Which programs define the company today?

Through early 2026, the lead narrative centered on primary sclerosing cholangitis, or PSC, a rare progressive liver disease without an FDA-approved disease-modifying therapy. Chemomab also maintained a Phase 2-ready systemic sclerosis program. The announced Scipher merger changes the intended first program to a precision-medicine Phase 2 trial in rheumatoid arthritis, while PSC becomes a potential partnering opportunity. CMMB remains Chemomab until closing, but its forward strategy is already being reframed.

Why is Chemomab important despite having no commercial product?

Chemomab matters as a test of whether a novel target can become an immunology platform. Its official nebokitug page says the antibody blocks immune-cell recruitment and fibroblast activation. The strategic value is therefore target validation: convincing clinical benefit could create partnering, licensing or acquisition economics.

How does Chemomab make money if it has no approved product?

Chemomab had generated no product revenue through March 31, 2026. Its model is asset development, not recurring sales: investor capital funds trials, drug supply, regulatory work and patents, producing evidence that may support a partnership, sublicense, merger or eventual launch. Value rises only as nebokitug’s probability of technical and commercial success improves.

Which revenue routes are realistic?

A direct launch offers maximum control but requires the most capital. A collaboration could transfer trial and commercialization costs to a larger partner for upfront cash, milestones and royalties. The proposed merger adds equity in the combined company and contingent value rights tied to nebokitug milestones. Scipher also brings precision-medicine testing, data and biopharma-partnership activities, although audited combined economics await later transaction filings.

What are the hidden economic obligations?

The founding license from Tel Aviv Souraski Medical Center includes development milestones, an exit fee capped at $3 million, sublicense participation and low-single-digit royalties. These obligations are modest relative to a successful drug’s potential value, but they reduce the net cash flows attributable to shareholders and belong in an asset-level valuation.

What makes nebokitug scientifically and strategically differentiated?

Nebokitug’s differentiation is mechanistic: it is intended to neutralize CCL24 and affect both immune-cell recruitment and fibroblast activation. The 2025 Form 20-F describes a single lead candidate tested across fibrotic and inflammatory settings. That breadth could support multiple indications, but it also concentrates risk in one target and molecule.

What did the SPRING trial actually establish?

SPRING enrolled 76 PSC patients in a 15-week randomized, placebo-controlled period. It met its safety and tolerability primary endpoint and produced secondary signals across liver stiffness, fibrosis biomarkers, bilirubin, liver tests and itch. The 20 mg/kg arm generally showed the stronger pattern and was selected for the planned pivotal design. Most eligible patients continued into the extension, allowing treatment for up to 48 weeks.

How should researchers interpret the clinical-event comparison?

Chemomab reported clinical events in 4.8% of moderate-to-advanced patients treated for up to 48 weeks versus 25.8% in matched historical controls. This is hypothesis-supporting, not randomized Phase 3 evidence; selection and follow-up differences can distort historical comparisons. The signal nevertheless informed an approximately 350-patient PSC pivotal design. Under the merger plan, a biomarker-guided rheumatoid-arthritis trial comes first, while PSC likely requires a partner.

What do Chemomab’s latest reported results show?

The latest standalone package covers the quarter ended March 31, 2026. Because Chemomab remained pre-revenue, cash, operating expense, net loss and dilution matter most. The first-quarter 2026 release showed lower spending as SPRING wound down, not commercial self-funding.

Which changes matter most year over year?

Why does the expense mix matter?

R&D and G&A were each $0.925 million in Q1 2026, splitting operating expense evenly between development and corporate functions. That mix reflects a small listed company between trials. Starting a new rheumatoid-arthritis study would raise R&D and reverse much of the recent burn reduction.

How did Chemomab reach the proposed Scipher merger?

Chemomab’s history is a sequence of target validation, public financing and strategic narrowing. Each turning point changed the maturity of nebokitug, access to capital or the preferred indication.

Which turning points still shape the business?

1. 2011
   Founded in Israel and licensed the CCL24 platform from Tel Aviv Souraski Medical Center, establishing the core intellectual property and royalty obligations.
2. 2021
   Combined with Anchiano Therapeutics and accessed Nasdaq, giving the program public-market financing capacity.
3. 2023
   FDA Fast Track status for adult PSC improved regulatory access without lowering the approval standard.
4. 2024
   SPRING met its safety endpoint and produced dose-related biomarker signals; new financing extended runway.
5. 2025
   Chemomab aligned with the FDA on a single event-driven PSC pivotal design, selected 20 mg/kg and changed the ADS ratio to 1:80.
6. May 2026
   Additional proteomic analyses broadened the biological rationale while standalone liquidity tightened.
7. July 2026
   The Scipher merger agreement shifted the initial combined-company plan toward biomarker-selected rheumatoid arthritis.

The recurring tension is clear: clinical evidence matured faster than the balance sheet needed to fund a pivotal PSC program. The merger is therefore a financing and development-platform solution, not merely corporate expansion.

Why does the Scipher transaction change the CMMB investment case?

Chemomab and Scipher signed a definitive agreement on July 7, 2026. The July 2026 Form 6-K targets a Q4 2026 close, subject to shareholder approval, an effective S-4, Nasdaq approval, tax rulings and at least $30 million of concurrent financing. Until closing, Chemomab and Scipher remain separate companies.

What exactly are Chemomab shareholders receiving?

What strategic assets does Scipher add?

The joint merger announcement describes Scipher’s network-medicine platform, rheumatoid-arthritis genomic data, records covering more than 3 million rheumatology patients, biopharma services and the PrismRA blood test. The strategic proposition is to identify patients most likely to respond to nebokitug and run a more informative Phase 2 trial.

Who competes with Chemomab, and where is its moat?

Chemomab lacks scale, commercial infrastructure and pipeline diversification. Its potential advantage combines a novel target, accumulated CCL24 know-how, clinical safety data, biomarker work and patents. Competition differs by indication: PSC is a race against other disease-modifying candidates, while rheumatoid arthritis is a crowded market where patient selection must create a measurable edge.

How does the competitive set differ by indication?

Which resources look durable under a VRIO-style lens?

The moat question is not whether CCL24 is unusual; it is whether that novelty produces controlled clinical benefit. Patents and know-how can protect a successful asset, but they cannot compensate for weak efficacy. The merger’s key experiment is whether Scipher’s biomarker platform improves patient selection enough to raise the signal-to-noise ratio.

How strong are Chemomab’s balance sheet and capital allocation?

Chemomab entered 2026 with no reported financial debt but limited liquidity. At March 31, 2026, liabilities were $1.113 million, equity was $10.695 million and cash plus short-term deposits was $8.043 million. Management’s standalone runway reached only the end of Q1 2027, and the 2025 results package carried a going-concern warning. The constraint is funding, not leverage.

Has management reduced the burn?

What do cash flow and liquidity say?

Who owns and governs Chemomab Therapeutics?

Chemomab has one class of ordinary shares with equal voting rights, represented by ADSs; since August 2025, one ADS equals 80 ordinary shares. Ownership was dispersed at December 31, 2025, with no disclosed controlling shareholder. That one-share-one-vote structure gives outside holders real voting relevance, especially because the merger requires approval and changes majority ownership.

What governance facts matter for shareholders?

Leadership also changes at closing: co-founder Adi Mor is expected to join the combined board, while Scipher CEO Reginald Seeto would lead the company. Until then, Chemomab’s management page identifies Mor as CEO and Neil Cohen as CFO. The transaction therefore transfers operational control while preserving limited legacy representation.

What opportunities and risks could change Chemomab’s outlook?

The merger enlarges the opportunity set and the analytical complexity. Potential upside comes from rheumatoid arthritis, biomarker selection, Scipher’s data platform and preserved PSC optionality. Each benefit still depends on transaction completion and a clinical program that has not begun.

Which milestones could create value?

Which risks are most material?

What is the key takeaway from Chemomab Therapeutics analysis?

Chemomab is a clinical-asset and transaction-outcome story, not a conventional earnings story. A revenue-based DCF is unsuitable because product revenue is zero, commercial timing is uncertain and the corporate structure may change before the next major readout. A useful model probability-weights legacy Chemomab, the proposed combined company and the CVRs separately.